Biotech and healthcare dominate this year’s VC-backed IPOs

Square’s widely anticipated IPO has captured a great deal of attention this week, but it’s biotech companies that should be getting the top billing. So far through mid-November, almost 60 percent of the IPOs of venture-backed companies on the Nasdaq and ...

This content is available for Venture Capital subscribers only. Request a free trial to get access for a limited period

Venture Capital

Subscribe Now Request Trial

If you already have an active Venture Capital subscription, please sign in to view this article.